Cherimoya seed extract
A cherimoya seed extract-based cosmetic composition addresses irritated skin issues by enhancing cannabinoid receptor-2 activity and inhibiting key inflammatory markers, effectively reducing itching and redness.
Patent Information
- Application Number
- KR1020217031148
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-03-01
- Filing Date
- 2020-02-27
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2040-02-27
AI Technical Summary
There is a demand for natural ingredients that alleviate symptoms of irritated skin, such as itching, dryness, and redness, which are not adequately addressed by current skincare products.
A skin care cosmetic composition containing a cherimoya seed extract, preferably in aqueous form, is formulated to soothe the skin, reduce irritation, and enhance the activity of cannabinoid receptor-2, inhibit signal transducer and activator of transcription 3 (STAT3), and inhibit the expression of IL-1β, IL-8, and calcitonin gene-related peptide (CGRP).
The cherimoya seed extract effectively reduces itching, redness, and pain perception in irritated skin, providing long-term benefits with minimal adverse effects.
Smart Images

Figure 112021111313850-PCT00001_ABST
Abstract
Description
Technology Field
[0001] The present invention generally relates to the field of cosmetics. More specifically, the present invention relates to cherimoya ( Annona cherimola The present invention relates to a skin care cosmetic composition comprising a seed extract of a plant. The present invention is based on the discovery that such seed extracts have several beneficial effects on the skin. These effects include soothing, soothing, moisturizing, and anti-itching effects of the seed extract of Cherimoya. In another aspect, the present invention thus provides a method for improving the appearance of the skin or reducing skin dryness in a subject, comprising administering the skin care composition of the present invention. In another aspect, the present invention provides a cosmetic method for soothing or calming irritation in the skin of a subject, comprising administering the skin care composition of the present invention. The present invention also relates to the use of the seed extract of Cherimoya for skin care, particularly for soothing irritated skin, calming irritation, improving the appearance of the skin, or reducing skin dryness and itching. Background Technology
[0002] There is strong demand for topical cosmetics that improve the appearance of the skin. These products must soften and moisturize the skin to delay signs of stress and aging. In recent years, many compounds commonly used in cosmetics have been replaced with natural ingredients, meeting consumer demand for more natural products.
[0003] In particular, plant and herb extracts are currently commonly used as additives in cosmetics, such as skin care products. Some plant extracts have been found to have very beneficial effects on the skin. For example, pink needle flower ( Epilobium angustifolium ) extract has been found to soothe the skin. Oat( Avena sativaOther extracts, such as ) extract, are known to soothe the skin from itching and irritation. Serotina cherry ( Prunus serotina The peel extract of ) has been found to provide powerful hydration to the skin. Therefore, plant or herb extracts are widely used in the cosmetics industry due to their diverse skin-improving properties. The problem to be solved
[0004] Despite significant progress in the discovery and development of natural ingredients for skincare products in the cosmetics industry, there is still a demand for other natural ingredients that alleviate symptoms of irritated skin, such as itching, dryness, and redness. means of solving the problem
[0005] Disclosure of the invention
[0006] The present invention relates to the cherimoya plant ( Annona cherimola This invention is based on the finding that seed extracts obtained from (preferably aqueous seed extracts) are highly suitable for use in skin products. In particular, the inventors have found that seed extracts of cherimoya are effective in soothing human skin and alleviating irritation. Furthermore, as shown in the examples described herein, cherimoya seed extracts enhance the activity of cannabinoid receptor-2, inhibit the activity of signal transducer and activator of transcription 3 (STAT3), and inhibit the expression of IL-1β, IL-8, and calcitonin gene-related peptide (CGRP). Finally, cherimoya seed extracts reduce itching and redness and reduce pain perception in irritated skin.
[0007] In a first aspect, the present invention provides a skin care cosmetic composition comprising a seed extract of the cherimoya plant as an active ingredient. The seed extract is preferably an aqueous seed extract. The seed extract is present in the skin care composition in an amount sufficient to induce at least one of the aforementioned skin improvement effects. Generally, a person skilled in the cosmetic field will be able to easily add the seed extract in an appropriate amount to the final skin care composition.
[0008] In a preferred embodiment, the seed extract is present in the skin care cosmetic composition in an amount of 0.05 to 25.0% (w / w). This is that the seed extract is present in a skin care cosmetic composition at about 0.05 to about 25.0% (w / w), about 0.05 to about 20.0% (w / w), about 0.05 to about 15.0% (w / w), about 0.05 to about 10.0% (w / w), about 0.05 to about 8.0% (w / w), about 0.1 to about 25.0% (w / w), about 0.1 to about 20.0% (w / w), about 0.1 to about 15.0% (w / w), about 0.1 to about 10.0% (w / w), about 0.1 to about 8.0% (w / w), about 0.5 to about 25.0% (w / w), about 0.5 to about 20.0% (w / w), about 0.5 to about 15.0% (w / w), About 0.5 to about 10.0% (w / w), about 0.5 to about 8.0% (w / w), about 0.1 to about 20.0% (w / w), about 0.5 to about 15.0% (w / w), about 1.0 to about 10.0% (w / w), about 1.0 to about 8.0% (w / w), about 2.0 to about 25.0% (w / w), about 2.0 to about 20.0% (w / w), about 2.0 to about 15.0% (w / w), about 2.0 to about 10.0% (w / w), about 2.0 to about 8.0% (w / w), about 3.0 to about 25.0% (w / w), about 3.0 to about 20.0% (w / w), about 3.0 to about 15.0% This means that it may be present in the range of (w / w), about 3.0 to about 10.0% (w / w), about 3.0 to about 8.0% (w / w), about 4.0 to about 25.0% (w / w), about 4.0 to about 20.0% (w / w), about 4.0 to about 15.0% (w / w), about 4.0 to about 10.0% (w / w), or about 4.0 to about 8.0% (w / w). In the most preferred embodiment, the seed extract is present in the cosmetic composition in an amount of about 0.5% to 3% (w / w).
[0009] As used herein, the term "plant extract" refers to a blend of compounds isolated from plants. Plant extracts may be prepared from one or more parts of a plant, e.g., whole plant, flower, seed, fruit, or leaves of a plant. Accordingly, the term "seed extract" refers to a blend of compounds isolated from the seeds of a plant. Extracts may be obtained by incubating seed material with a solvent according to standard procedures described in the art. The term includes crude extracts as well as extracts that have undergone one or more concentration or purification procedures. The seed extracts of the present invention may exist in liquid form, preferably in solution form, or in solid form, e.g., in dry powder form.
[0010] Seed extracts can be prepared based on cherimoya seeds removed from the fruit of the plant. To prepare the seeds, the fruit is cut open and the fruit pulp is removed. Then, the seeds may be dried and further processed. Drying can be performed at a temperature of 20°C to 80°C, preferably 25°C to 70°C, and most preferably 30°C to 50°C. A drying temperature of 40°C is particularly preferred. The weight loss resulting from drying should be in the range of 1% to 20% (w / w), preferably 2.5% to 12% (w / w), and more preferably 5% to 10%.
[0011] Before disintegration, plant material can be blanched at a temperature between 45°C and 100°C to remove bacterial contamination and improve digestibility. Furthermore, blanching reduces the activity of enzymes such as hydrolase, lipase, and oxidase, thereby increasing the stability and quality of the plant material.
[0012] Then, the seeds are disintegrated before contacting them with a solvent. Disintegration can be performed, for example, by repeated freezing and thawing, or by suitable devices such as homogenizers, high-pressure homogenizers, ultrasonic homogenizers, grinders, or grinders. For example, a standard ball mill or French press may be used. The seeds can be disintegrated in a frozen or non-frozen form. Additionally, cell degradation of the seed material may be achieved enzymatically. To this end, the seed hulls can be removed and treated with appropriate enzymes to destroy the structural components of the cells. Incubating the seed material with pectinase, collagenase, cellulase, and / or hemicellulase is suitable for effectively degrading the cells.
[0013] In the next step, the disintegrated seed material is brought into contact with a solvent suitable for extraction. The solvents suitable for extraction are water, aqueous buffers, e.g., phosphate-buffered saline or citrate buffer, glycols, e.g., propylene glycol or butylene glycol, or glycol-water mixtures, alcohols or alcohol-water mixtures, particularly ethanol or ethanol-water mixtures, or methanol or methanol-water mixtures, glycerin or glycerin-water mixtures.
[0014] The seed extract used in the preparation of the skin care composition of the present invention is preferably an aqueous seed extract, that is, an extract prepared with an aqueous solvent, preferably water or an aqueous buffer. This has the particular advantage that the extract does not contain a significant amount of acetogenin. Simply put, acetogenin is a class of polyketides found in plants of the Annonaceae family. To date, more than 400 types of acetogenins are known, many of which are neurotoxic. Since acetogenin is almost insoluble in water, it does not accumulate in aqueous extracts. When preparing seed extracts with organic solvents, acetogenin must be removed from the extract before formulation into a skin care product.
[0015] In another preferred embodiment, an aqueous seed extract is used in a skin care composition of the present invention that contains no acetogenin or contains only a small amount. As a result, the skin care cosmetic composition of the present invention contains acetogenin in an amount of less than 0.001% (w / w), more preferably less than 0.0001% (w / w), and even more preferably less than 0.00001% (w / w). In a particularly preferred embodiment, it is preferable that the skin care composition of the present invention be free of acetogenin.
[0016] In another preferred embodiment, an aqueous seed extract is used in a skin care composition of the present invention that contains no phytosterols or contains only a small amount. As a result, the skin care cosmetic composition of the present invention contains phytosterols in an amount of less than 0.001% (w / w), more preferably less than 0.0001% (w / w), and even more preferably less than 0.00001% (w / w). In a particularly preferred embodiment, the skin care cosmetic composition of the present invention preferably does not contain phytosterols.
[0017] Mass spectrometry analysis of the extract prepared according to the example below revealed that the extract contains the alkaloids isoboldin, reticulin, coridin, micellarbin, and riboflavin, as well as cherimolacyclopeptides A, B, C, D, E, and F. Accordingly, in another preferred embodiment, an aqueous seed extract is used in a skin care cosmetic composition of the present invention comprising at least one peptide selected from the group of cherimolacyclopeptides A, B, C, D, E, and F. More preferably, an aqueous seed extract comprising cherimolacyclopeptide AF is used. In another preferred embodiment, an aqueous seed extract is used in a skin care cosmetic composition of the present invention comprising at least one alkaloid selected from the group of isoboldin, reticulin, coridin, micellarbin, and riboflavin. More preferably, an aqueous seed extract comprising all of these alkaloids is used.
[0018] In a preferred embodiment, the solvent is water. In another preferred embodiment, the solvent is preferably a sodium-citrate buffer according to Soerensen, for example, a buffer containing 0.1 N HCl and 0.1 M disodium citrate with a pH of 1.2 to 5.0, preferably 2.0 to 5.0, for example, pH 3.0. In another preferred embodiment, the solvent is preferably a sodium-citrate buffer according to Soerensen, for example, a buffer containing 0.1 M trisodium citrate dihydrate and 0.1 M citric acid monohydrate (C6H8O7xH2O) with a pH of 5.0. In another preferred embodiment, the solvent is preferably a phosphate buffer according to Sørensen, e.g., 0.06 M potassium phosphate and 0.06 M disodium phosphate, having a pH of 5 to 8, e.g., pH 5, containing 0.06 M potassium phosphate and 0.06 M disodium phosphate. During extraction, the ratio of seed material to solvent may be in the range of 1:100 (w / w) to 50:100 (w / w). Preferably, during extraction, the ratio of seed material to solvent is 5:100 (w / w) or more, 10:100 (w / w) or more, 15:100 (w / w) or more, 20:100 (w / w) or more, 25:100 (w / w) or more, 30:100 (w / w) or more, 35:100 (w / w) or more, 40:100 (w / w) or more, 45:100 (w / w) or more, or 50:100 (w / w).
[0019] After extraction, the liquid phase is separated from the solid plant material by, for example, gradient separation, centrifugation, filtration, or a combination of these methods. For example, a standard decanter device such as the CA 22 device (GEA Westfalia Separator Group GmbH, Oelde, Germany) may be used. The extraction mixture produced in the decanter may undergo an additional filtration step, such as membrane filtration. The liquid phase obtained in this way is considered to be the abstract according to the present invention.
[0020] The extract can be used directly to formulate the skin care composition of the present invention. However, to stabilize the extract, it is desirable to keep the extract at ambient temperature for several hours, preferably for 8 to 16 hours, for 1 to 24 hours. The extract can then be filtered again to remove residual solids. For this purpose, a 0.2 μm cellulose acetate membrane can be used.
[0021] The skin care cosmetic composition of the present invention is preferably formulated for topical application, which means that the composition is provided in a form that allows the composition to be dispensed after application to the skin by a consumer. Preferably, the skin care composition of the present invention is formulated as a liquid, ointment, cream, scrub, lotion, paste, gel, hydrogel, foam, or powder. If the composition is formulated as a liquid, it may be packaged in a pump dispenser that allows the liquid to be sprayed onto the skin area to be treated. The skin care composition of the present invention may also be included in a patch applied to the skin.
[0022] In a particularly preferred embodiment, the composition of the present invention is formulated for topical application to the skin of a subject. The skin to be treated may include skin of the face and body, such as the neck, chest, back, arms, hands, legs, or thighs. According to a preferred embodiment, the skin to be treated with the composition of the present invention is the skin of the face. According to another preferred embodiment, the skin to be treated with the composition of the present invention is the skin of the body.
[0023] The skin care composition may be applied to areas of skin requiring treatment, such as the face or body, at least once a day, twice a day, or more frequently if necessary. When applied twice a day, the first and second applications are preferably spaced at least 6 hours apart, preferably 8 hours apart. Typically, the cosmetic composition is applied once in the morning and once in the evening. The composition of the present invention may be used over a long period without adverse effects. For example, the treatment period may be at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 6 weeks, at least 12 weeks, at least 24 weeks, or longer. In some embodiments, the treatment will be extended for several months, such as 4 months, 6 months, 8 months, 12 months, 18 months, or 24 months.
[0024] Apart from the seed extract, the skin care composition of the present invention comprises at least one dermatologically acceptable carrier. The carrier may be present in the skin care composition of the present invention in an amount of about 30% to about 99% by weight of the skin care composition of the present invention, preferably about 40% to about 98%, more preferably about 50% to about 97%, even more preferably about 60% to about 96%, and even more preferably about 70% to about 95%. The dermatologically acceptable carrier used in the present invention is compatible with both the skin and the other components of the composition. In particular, the dermatologically acceptable carrier does not irritate the skin or otherwise have an adverse effect. Additionally, the dermatologically acceptable carrier does not interfere with the activity, solubility, or dispersibility of other components in the composition. Suitable dermatologically acceptable carriers may include, but are not limited to, aqueous solutions, emulsions, dispersions, and solids. In a preferred embodiment, the dermatologically acceptable carrier is an emulsion. The emulsion may be an oil-in-water emulsion, an oil-in-water emulsion, or an oil-in-water emulsion. When the emulsion is used as a carrier, it is preferable that the aqueous phase of the emulsion contains cherimoya seed extract. The emulsion may contain one or more anionic, cationic, or nonionic emulsifiers in an amount of, for example, 1% to about 5% based on the weight of the carrier.
[0025] The composition of the present invention may further include additional optional ingredients commonly used in skin care cosmetic products. These ingredients are described in detail, for example, in the literature International Cosmetic Ingredient Dictionary and Handbook, 16th ed. (2016). For example, the composition of the present invention may also include one or more of antioxidants, binders, pH adjusters, buffers, colorants, thickeners, emollients, humectants, exfoliants, preservatives, plant extracts, essential oils, and fragrances.
[0026] For example, the composition of the present invention may include an exfoliating compound such as urea. Examples of exfoliating compounds useful in the composition of the present invention include, but are not limited to, urea, alpha-hydroxy acids and beta-hydroxy acids, and their esters, anhydrides, and salts. Suitable hydroxy acids include, for example, urea, glycolic acid, lactic acid, malic acid, mandelic acid, tartaric acid, citric acid, 2-hydroxyalkano acids, salicylic acid, and derivatives thereof. The use of urea is particularly preferred because it has an additional moisture-binding effect and improves the absorption of other cosmetic ingredients. The skin care composition of the present invention may include about 1% to about 5% (w / w) of an exfoliating compound. In some embodiments, the composition may contain two or more different exfoliating compounds.
[0027] In a preferred embodiment, the skin care composition of the present invention comprises a compound that acts as a pH adjuster. Since the composition of the present invention is used on human skin, it generally has a weakly acidic pH to be more suitable for the acidic environment of the skin. The composition may have a pH in the range of about 2.5 to about 6.5, preferably about 4.0 to about 6.0, more preferably about 5.0 to about 6.0, or about 5.5 to about 6.0. An acidic pH can be achieved by adding an acid, for example, a carboxylic acid such as an alpha hydroxy acid, to the skin care composition of the present invention. The properties of the acid that can be used in the composition of the present invention are not particularly limited. Suitable acids include formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, etc. In a particularly preferred embodiment, the composition comprises lactic acid as a pH adjuster. Lactic acid is particularly useful for application to human skin because it is also secreted by skin flora and forms an acidic environment that protects the surface of human skin.
[0028] The skin care composition of the present invention may also include an emollient. Suitable emollients for the skin care composition of the present invention include, but are not limited to, olive oil, palm oil, soybean oil, sesame oil, rapeseed oil, evening primrose oil, sunflower oil, avocado oil, olive oil, coconut oil, castor oil, safflower oil, myristyl lactate, isopropyl myristrate, polyethylene glycol, isopropyl palmitate, isopropyl stearate, isobutyl palmitate, isocetyl stearate, or cetyl alcohol. The skin care composition of the present invention may include about 1% to about 5% (w / w) of an emollient. In some embodiments, the composition may contain two or more different emollients.
[0029] The skin care composition of the present invention may also include a moisturizer for improving skin moisture. Suitable moisturizers for use in the composition of the present invention include, but are not limited to, glycerin, polyethylene glycol ether of glycerin, amino acids such as proline and arginine, sugars and sugar alcohols such as glucose, mannose, trehalose and polyglycerol sorbitol, 1,3-butylene glycol, propylene glycol, diglycerol, glycerol monopropoxylate, glycogen, sodium hyaluronate, sodium poly-aspartate, sodium polyglutamate, sorbet 20, sorbet 6, and hydrogenated starch hydrolysate. The skin care composition of the present invention may include about 1% to about 5% (w / w) of a moisturizer. In some embodiments, the composition may contain two or more different moisturizers.
[0030] The skin care composition of the present invention preferably comprises at least about 30% (w / w) of water. More preferably, the skin care composition comprises at least about 35% (w / w) water, at least about 40% (w / w) water, at least about 45% (w / w) water, at least about 50% (w / w) water, at least about 55% (w / w) water, at least about 60% (w / w) water, at least about 65% (w / w) water, at least about 70% (w / w) water, at least about 75% (w / w) water, at least about 80% (w / w) water, at least about 85% (w / w) water, or at least about 90% (w / w) water. Most preferably, the amount of water in the final skin care composition is at least about 70% (w / w).
[0031] In another aspect, the present invention provides a cosmetic method for improving the appearance of a subject's skin, comprising administering a composition as described in another part of this specification to the skin of a subject. In another aspect, the present invention provides a cosmetic method for reducing skin dryness of a subject, comprising administering a composition as described in another part of this specification to the skin of a subject. In another aspect, the present invention provides a cosmetic method for soothing irritated skin, comprising administering a composition as described in another part of this specification to the skin of a subject. In another aspect, the present invention provides a cosmetic method for soothing irritated skin, comprising administering a composition as described in another part of this specification to the skin of said alternative. In a particularly preferred embodiment, the above method comprises topically administering a composition to facial skin. In another particularly preferred embodiment, the cosmetic method achieves a desired effect by one or more of the following actions: agonizing of cannabinoid receptor-2, enhancing the activity of cannabinoid receptor-2, inhibiting or reducing the activity of signal transducers and transcription activator 3 (STAT3), inhibiting the expression of IL-1β, inhibiting the expression of IL-8, and inhibiting the expression of calcitonin gene-related peptide (CGRP).
[0032] In another aspect, the present invention provides a use for cosmetic skin care of a composition as described elsewhere in this specification, namely, a composition comprising a seed extract of cherimoya as an active ingredient. Specifically, the composition is used to soothe irritated skin, relieve irritation of irritated skin, improve and / or improve skin appearance, or reduce skin dryness and itching. Preferably, the use of the seed extract is based on one or more of the following activities: agonizing of cannabinoid receptor-2, enhancing the activity of cannabinoid receptor-2, inhibiting or reducing the activity of signal transducers and transcription activator 3 (STAT3), inhibiting the expression of IL-1β, inhibiting the expression of IL-8, and inhibiting the expression of calcitonin gene-related peptide (CGRP).
[0033] As used herein, unless otherwise specifically stated, all percentages are based on the weight of the skin care cosmetic composition. Unless otherwise specified, all ratios are weight ratios. Brief explanation of the drawing
[0034] Figure 1 shows that extract F230 acts as a cannabinoid receptor-2 agonist. 293T-CB2-CRE-luc cells were treated with extract F230 or the positive control WIN-55,212-2 for 15 minutes. Subsequently, the cells were incubated with 10 μM Forskolin. After 6 hours of incubation, the cells were lysed and luciferase activity was measured. Specific transactivation observed for F230 is indicated as [%] of Forskolin stimulation. Figure 2 indicates that extract F230 possesses STAT3-inhibitory activity. HeLa-STAT3-luc cells were treated with F230 and stimulated with IFN-γ. After 6 hours, the cells were lysed and luciferase activity was measured. The results were expressed as the percentage inhibition of STAT3 activity induced by IFN-γ (100% activation). Experiments were performed three times for each F230 concentration. Figure 3 shows that F230 extract effectively reduces capsaicin-induced release of cytokine IL-1β in co-cultures of keratinocytes and human sensory neurons. Figure 4 shows that F230 extract effectively reduces capsaicin-induced release of cytokine IL-8 in co-cultures of keratinocytes and human sensory neurons. Figure 5 shows that extract F230 reduces capsaicin-induced CGRP expression. As the amount of F230 increases, the level of inhibition of CGRP expression increases. Figure 6 shows that the F230 extract significantly reduces skin itching compared to a placebo, even after 1 minute of application. Figure 7 shows that the F230 extract significantly reduces skin redness compared to the placebo after 17 days of application. Figure 8 shows that extract F230 increases the skin's sensory threshold compared to a placebo. Specific details for implementing the invention
[0035] Examples
[0036] The following examples describe specific preferred embodiments of the present invention. However, it should be noted that the present invention is not limited to these embodiments.
[0037] Example 1: Cherimoya ( Annona chemimola Preparation of seed extracts
[0038] The cherimoya extract was prepared as follows. The cherimoya fruits were opened and the pulp was removed. The seeds were harvested and dried overnight at a temperature of 40°C. After drying, the seeds were disintegrated by milling. Subsequently, the disintegrated seeds were treated with 0.1 M citric acid monohydrate (C6H8O7 · H2O) and 0.1 M trisodium citrate, dihydrate C6H5O7Na3 · Extraction was performed at 50°C for 4 hours using a sodium-citrate buffer containing 2H2O, pH 6.0.
[0039] After extraction, the liquid phase was separated from the solid plant material using a decanter CA 22 device (Westfalia Separator AG). The liquid fraction was maintained at room temperature for 16 hours for stabilization and then subjected to a final filtration step using a 0.2 μm cellulose acetate membrane. The extract obtained in this way is hereinafter referred to as "F230". Mass spectrometry analysis of extract F230 revealed that it contains the alkaloids isoboldine, reticulin, coridine, micellalbin, and riboflavin, as well as cherimolacyclopeptides A, B, C, D, E, and F (see References 1-10).
[0040] Example 2: Cannabinoid Receptor-2 Action Activity
[0041] Cannabinoid receptor 2 (CB2) is part of a complex regulatory system associated with inflammation. Above all, the activity of this receptor is involved in thermoregulation, cell growth, host defense, apoptosis, pruritus, pain, and wound healing (Soethoudt et al. (2017), Nat. Com-mun. 8, 13958; Ibsen (2017), Cannabis and Cannabinoid Research 2:1, 48-60). Activation of CB2 induces the inhibition of inflammatory cytokines and pain-inducing neuropeptides such as CGRP (Calcitonin Gene-Related Peptide). Therefore, compounds that enhance CB2 activity are potentially useful for alleviating inflammatory skin conditions associated with, for example, atopic dermatitis, psoriasis, and pruritus.
[0042] To evaluate the potential effects of the F230 extract prepared as described in Example 1, 1 x 10⁶ cells of 293T-CB2 cells stably transfected with cDNA encoding human cannabinoid receptor 2 (CB2) were placed in a 24-well plate. 5 Cells were incubated at a cell / ml density and transiently transfected with 0.1 μg / ml of the plasmid CRE-luc, which contains six consensus cAMP-reactive elements (CRE) conjugated to firefly luciferase. Transient transfection was performed with Rotifect (Carl Roth GmbH, Karlsruhe, Germany) according to the manufacturer's instructions. Cells were harvested 24 hours after transfection.
[0043] To measure the CB2-acting activity of F230, 293T-CB2-CRE-luc cells were treated with increasing concentrations of F230 extract or positive control WIN-55,212-2 (Sigma Aldrich, Taufkirchen, Germany) for 15 minutes, followed by 10 μM Forskolin (Sigma Aldrich, Taufkirchen, Germany). After 6 hours of stimulation, cells were lysed in 25 mM Tris-phosphate pH 7.8, 8 mM MgCl2, 1 mM DTT, 1% Triton X-100, and 7% glycerol. Luciferase activity was measured using an Autolumat LB 9501 (Berthold Technologies, Bad Wildbad, Germany) according to the instructions of the Luciferase Assay Kit (Promega, Madison, USA). In each experiment, the background value obtained with the lysis buffer was subtracted, and specific metastatic activation was expressed as [%] of Forskolin stimulation (the latter was set to 100%).
[0044] result The results are shown in Figure 1. The analysis results reflect CB2 agonist activity as inhibition of Forskolin-induced CRE-Luc activity. It can be seen that the positive control, WIN-55,212-2, acts as a CB2 agonist and partially antagonizes the effect of Forskolin. The same effect is observed for F230, while the level of Forskolin antagonism increases as the amount of F230 increases. Consequently, this analysis demonstrates that F230 exerts CB2 agonist activity.
[0045] Example 3: STAT3 Inhibitory Activity
[0046] Signal transducer and transcription activator 3 (STAT3) is a human transcription factor encoded by the STAT3 gene. During the progression of skin inflammation, IFN-γ stimulates the expression of STAT3, which in turn induces the expression of additional pro-inflammatory cytokines, thereby contributing to inflammation (Archer et al. (2017), The Journal of Immunology, 198 (1 Appendix) 197.4). Inhibition of IFN-γ-stimulated STAT3 expression is thought to reduce the inflammatory immune response of the skin.
[0047] To evaluate the potential effect of the F230 extract prepared as described in Example 1 on STAT3 activity, HeLa-STAT3-luc cells stably transfected with plasmid 4xM67 pTATA TK-Luc were used. Cells were placed in 2x10 96-well plates the day before analysis. 4 Cells were inoculated at a density of cells / ml. Then, the cells were treated with F230 for 15 minutes and then stimulated with 25 U / ml IFN-γ.
[0048] After 6 hours, the cells were washed twice with phosphate-buffered saline (PBS) and lysed by incubating for 15 minutes in 50 μl of lysis buffer containing 25 mM tris-phosphate (pH 7.8), 8 mM MgCl2, 1 mM DTT, 1% Triton X-100 (Sigma Aldrich, Taufkirchen, Germany), and 7% glycerol (Sigma Aldrich, Taufkirchen, Germany) at room temperature in a horizontal shaker.
[0049] Luciferase activity was measured using a Berthold / LB 941 plate reader (Berthold Technologies) according to the instructions of the Luciferase Analysis Kit (Promega, Madison, WI, USA). Relative Luminescence Units (RLU) were calculated, and the results were expressed as the percentage inhibition of STAT3 activity induced by IFN-γ (100% activated). Experiments for each concentration of the test item were performed three times in each well.
[0050] Results: The results are shown in Figure 2. As shown in the figure, F230 neutralizes STAT3 activity induced by IFN-γ. As the amount of F230 increases, the level of STAT3 inhibition increases.
[0051] Example 4: Inhibition of IL-1β and IL-8 expression
[0052] IL-1β and IL-8 are pro-inflammatory cytokines involved in numerous skin diseases associated with inflammation, such as psoriasis, atopic dermatitis, neutrophilic dermatitis, and eczema (Jensen (2010); Current opinion in investigational drugs (London, England: 2000); 11(11), 1211-20); Bou-Dargham et al. (2017), Med. Res. Rev., 37: 180-216; Amarbayasgalan et al. (2013), Int Arch Allergy Immunol, 160:63-74). Therefore, inhibiting the production of these cytokines helps alleviate skin inflammation.
[0053] To determine whether the F230 extract prepared as described in Example 1 could inhibit the expression of IL-1β and IL-8, a co-culture system of keratinocytes and human sensory neurons was used. Human sensory neurons were derived from human induced pluripotent stem cells (hiPS cells). hiPS cells were obtained by transfecting human fibroblasts reprogrammed into neurons. HiPS cells were plated in 6-well plates coated with a thin layer of Matrigel® (Corning GmbH, Kaiserslautern, Germany) at a cell density of 250,000 in a medium consisting of DMEM-F12 (Pan-Biotech, Aidenbach, Germany) supplemented with 10% knockout serum substitute (Life Technologies, Carlsbad, USA), 0.1 μM retinoic acid (Sigma Aldrich, Taufkirchen, Germany), 1% P / S (Pan-Biotech), and an inhibitor cocktail. The culture was maintained at 37℃ and 5% CO2 for 6 days.
[0054] Six days after differentiation, hiPS cells were plated at a density of 20,000 cells in differentiation medium using 96-well plates coated with a thin layer of Matrigel®. After nine days, the culture medium was replaced with maturation medium, namely DMEM-F12 fortified with 1% N2 (Life technologies, Carlsbad, USA), 10 ng / mL Neurotrophin-3 (NT-3), 10 ng / mL Glial-derived Neurotrophic Factor (GDNF, Pan-Biotech), 10 ng / mL Brain-derived Neurotrophic Factor (BDNF, PanBiotech), and 10 ng / mL Nerve Growth Factor (NGF, Sigma). Commercial human keratinocytes were thawed and proliferated in 75 cm² culture flasks of keratinocyte growth medium. Once proliferation was complete, the cells were detached and frozen in liquid nitrogen. On day 14 of neuron culture, keratinocytes were thawed again and plated on top of the neurons in a 96-well plate at a density of 30,000 cells per well in a medium consisting of 2 / 3 maturation medium and 1 / 3 keratinocyte growth medium. The medium was replaced every 2 or 3 days. On day 18, the medium was removed and new medium was added, namely: (i) control medium, or (ii) medium containing capsaicin, or (iii) medium containing capsaicin and capsazepine, or (iv) medium containing capsaicin and F230 at three different concentrations. One hour after capsaicin stimulation, the supernatant was removed and cytokine release was analyzed. Samples were evaluated using cytometry flux (BD Bioscience) and compared to an untreated control.
[0055] resultThe results of measuring IL-1β secretion are shown in Figure 3. Incubation with capsaicin strongly induced IL-1β expression. Conversely, when cells were co-cultured with capsazepine before or during cell activation using capsaicin, IL-1β secretion was completely stopped. Similarly, as the amount of F230 increased, the level of inhibition of IL-1β expression increased. The results of measuring IL-8 secretion are shown in Figure 4. Incubation with capsaicin strongly induced IL-8 expression, whereas co-cultured with capsazepine before or during cell activation by capsaicin significantly reduced IL-8 secretion. Likewise, as the amount of F230 increased, the level of inhibition of IL-8 expression increased.
[0056] Example 5: Inhibition of CGRP
[0057] Calcitonin gene-related peptide (CGRP) is a member of the calcitonin family of peptides that acts as a neuropeptide. The release of CGRP is associated with neuroinflammation caused by vasodilation that induces erythema and pain. CGRP production is induced by capsaicin. Using the co-culture approach with human sensory neurons and keratinocytes described above, the amount of CGRP released into the supernatant was measured after stimulation with 10 μM capsaicin for 30 minutes. Antibodies-online (ELISA) was used for CGRP detection. The results obtained were compared with untreated cells.
[0058] result The results are shown in Figure 5. As shown in the figure, F230 neutralizes capsaicin-induced CGRP expression. As the amount of F230 increases, the level of inhibition of CGRP expression increases.
[0059] Example 6: Reduction of skin itching
[0060] For in vivo studies, a composition containing F230 and a placebo composition were prepared.
[0061] A composition containing 3% F230 was prepared as follows:
[0062] A. Deionized water 237.875 g
[0063] B. Xanthan gum 2.50 g
[0064] C. Euxyl PE9010 2.00 g
[0065] D. F230 7.5
[0066] E. Citric acid (10%) 0.125 g
[0067] Mix components A and B and disperse them homogeneously. Then, add components CE in the given order. Finally, adjust the pH to 5.71.
[0068] The placebo composition was prepared as follows:
[0069] A. Deionized water 238.00 g
[0070] B. Xanthan gum 2.50 g
[0071] C. Euxyl PE9010 2.00 g
[0072] D. Deionized water 7.50 g
[0073] Components A and B are mixed and homogeneously dispersed. Then, component CD is added in the given order. The pH of the composition was adjusted to 5.70.
[0074] To investigate the effect of F230 on skin itching, a composition containing 3% F230 was applied to itchy skin. A double-blind study was conducted on 42 healthy volunteers (9 men and 33 women). 22 volunteers were assigned to F230 treatment, and 20 volunteers were assigned to placebo treatment. Some of the volunteers had a history of dry and itchy skin, including 11 subjects with atopic dermatitis, 8 subjects with type IV allergy, 1 subject with psoriasis, and 1 subject with type II diabetes. 12 volunteers had sensitive skin. 9 volunteers had normal skin. Itching was scored at time points t=0, 1 minute, 5 minutes, and 24 hours. The baseline at t=0 was set to 0%. The frequency of itching was evaluated by the subjects on a 5-point scale before and after the use of the test composition.
[0075] result The results are shown in Figure 6. It can be seen that 1 minute after application, itching was already significantly reduced by F230 compared to the placebo.
[0076] Example 7: Reduction of skin redness
[0077] To investigate the effect of F230 on skin redness, a formulation containing 3% F230 was applied to skin with abnormal redness. Volunteers from Example 6 were used in this study. The formulation was applied twice daily. Redness was scored at t=0 and 17 days after application. The baseline at t=0 was set to 0%. Before and after the test period, a skilled scorer evaluated all erythema caused by scratching on the subjects' skin.
[0078] result The results are shown in Figure 7. It can be seen that F230 reduced redness caused by scratching compared to placebo after 2 weeks of application (Day 17) compared to baseline (Day 1).
[0079] Example 8: Reduction of skin sensitivity
[0080] To investigate the neurosedative effect of F230 on skin sensitivity, a formulation containing 3% F230 was applied to the skin. Volunteers participating in Example 6 were used in the study. The formulation was applied once. Skin sensitivity was determined by measuring at 250 Hz and 5 Hz using a Neurometer® CPT / C device (Neurotron Inc., Bal-timore, USA) at t=0 (i.e., immediately before application) and 40 minutes after the application of the test formulation or placebo. The baseline at t=0 was set to 0%.
[0081] result The results are shown in Figure 8. At both 250 Hz and 5 Hz, it can be seen that the sensory threshold after treating the skin with F230 is much higher compared to the placebo.
[0082] List of references
[0083] 1) Li C.-M., et al. (1997), Phytochemistry, 45, 521–523,
[0084] 2) Li C.-M., et al. (1998), Phytochemistry, 47, 1293―1296,
[0085] 3) Li C.-M., et al. (1998), Phytochemistry, 48, 555―556,
[0086] 4) Li C.-M., et al. (1997), Phytochemistry, 50, 1047―1052,
[0087] 5) Morita H., et al. (1999), Tetrahedron, 55, 7509–7518,
[0088] 6) Wele A., et al. (2005), Phytochemistry, 66, 1154―1157,
[0089] 7) Wele A., et al. (2002), Tetrahedron, 60, 405―414,
[0090] 8) Wele A., et al. (2004), J. Natural Prod., 67, 1577―1579,
[0091] 9) Wele A., et al. (2005), Phytochemistry, 66, 693―696,
[0092] 10) Wele A., et al. (2005), Phytochemistry, 66, 2376―2380.
Claims
Claim 1 Cherimoya Annona cherimola A cosmetic composition for skin care (excluding the scalp), comprising an aqueous seed extract of a plant, wherein the aqueous seed extract comprises at least one peptide selected from the group consisting of cherimolacyclopeptides A, B, C, D, E, and F, and wherein the composition is intended to soothe, calm, or reduce skin itching of an irritated subject. Claim 2 A cosmetic composition according to claim 1, wherein the extract is present in an amount of 0.05 to 25.0% (w / w) or 0.5 to 5.0% (w / w) in the composition. Claim 3 In claim 1, the composition is a cosmetic composition formulated for topical application. Claim 4 In paragraph 3, the composition is a cosmetic composition formulated for topical application to facial skin or body skin. Claim 5 A cosmetic composition according to claim 1, wherein the composition is formulated as an ointment, cream, lotion, paste, gel, hydrogel, foam, or powder. Claim 6 A cosmetic composition according to claim 1, wherein the composition comprises a softening agent selected from the group consisting of olive oil, palm oil, soybean oil, sesame oil, rapeseed oil, evening primrose oil, sunflower oil, avocado oil, coconut oil, castor oil, safflower oil, myristyl lactate, isopropyl myristrate, polyethylene glycol, isopropyl palmitate, isopropyl stearate, isobutyl palmitate, isocetyl stearate, or cetyl alcohol. Claim 7 A cosmetic composition according to claim 1, wherein the composition has a pH in the range of 2.5 to 6.5 or 4.0 to 6.
0. Claim 8 A cosmetic composition according to claim 1, wherein the composition comprises a moisturizer selected from the group consisting of glycerin, polyethylene glycol ether of glycerin, amino acids including proline and arginine, sugars and sugar alcohols including glucose, mannose, trehalose and polyglycerol sorbitol, 1,3-butylene glycol, propylene glycol, diglycerol, glycerol monopropoxylate, glycogen, sodium hyaluronate, sodium poly-aspartate, sodium polyglutamate, sorbet 20, sorbet 6, and hydrogenated starch hydrolysate. Claim 9 A cosmetic composition according to claim 1, wherein the composition comprises an exfoliating compound selected from the group consisting of urea, alpha-hydroxy acid and beta-hydroxy acid, and their esters, anhydrides and salts. Claim 10 delete Claim 11 delete Claim 12 delete Claim 13 delete Claim 14 delete Claim 15 delete
Citation Information
Patent Citations
Anti-oxidant or Anti-aging cosmetic composition
KR1020110057954A
Composition for head
JP1997012433A
Fibroblast-activator and skin lotion containing the same
JP2006249051A
